✦ LIBER ✦

Laryngeal tardive dyskinesia

✍ Scribed by A. Féve; B. Angelard; J. Lacau St Guily

Publisher: Springer
Year: 1995
Tongue: English
Weight: 418 KB
Volume: 242
Category: Article
ISSN: 0340-5354
DOI: 10.1007/bf00873549

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hydroxyzine-associated tardive dyskinesi

Hydroxyzine-associated tardive dyskinesia

✍ Beverly G. Clark; Mark Araki; Harold W. Brown 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

Risperidone and tardive dyskinesia

✍ Hal Morgenstern; William M. Glazer; Scott W. Woods 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 37 KB

hallucinations. Almost half of our patients had sleep disturbance in contrast to 8±23% reported by Deutsch and Rovner (1991). There were many disturbances of biological function in our dementia patients, jeopardizing the patients and burdening the caregivers. However, methodological variations in th

Bereitschaftspotential in tardive dyskin

Bereitschaftspotential in tardive dyskinesia

✍ Dr. Lawrence E. Adler; Mark Pecevich; Herbert Nagamoto 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 518 KB

The bereitschaftspotential or motor readiness potential is a slow negative electroencephalographic wave occurring 150-1500 ms prior to the onset of a voluntary movement. It was measured in 33 subjects: 11 normal controls, 11 medicated schizophrenics with no tardive dyskinesia or evidence of drug-ind

Clozapine in tardive dyskinesia

✍ George M. Simpson; J. Hillary Lee; Ram K. Shrivastava 📂 Article 📅 1978 🏛 Springer 🌐 English ⚖ 468 KB

Naloxone in tardive dyskinesia

✍ I. Blum; P. F. Nisipeanu; E. Roberts 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 90 KB

Sulpiride in tardive dyskinesia

✍ Daniel E. Casey; Jes Gerlach; Hans Simmelsgaard 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 407 KB

Tardive dyskinesia can be suppressed by drugs that block dopaminergic receptors, but often at the cost of a concomitant increase in parkinsonism. Sulpiride (400 -- 2100 mg/day), a selective type-2 dopamine receptor antagonist, was evaluated in a blind, placebo-controlled trial in 11 patients with ta